Cancer. Encouraging results for second-generation antiangiogenesis drugs.
Marx
Jean
J
D020533:Angiogenesis Inhibitors / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D046152:Gastrointestinal Stromal Tumors / Q000098:blood supply / Q000188:drug therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D000077157:Sorafenib; D014481:United States; D014486:United States Food and Drug Administration; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; D011505:Protein-Tyrosine Kinases